An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

[1]  J. Gustafsson.  Fatty acids in control of gene expression. , 2009, Nutrition reviews.

[2]  M. Tetel.  Nuclear Receptor Coactivators in Neuroendocrine Function , 2000, Journal of neuroendocrinology.

[3]  J. Auwerx,et al.  p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively* , 1999, The Journal of Biological Chemistry.

[4]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[5]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[6]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Colville-Nash,et al.  Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. , 1998, Journal of immunology.

[8]  R. Roeder,et al.  The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Hueng-Sik Choi,et al.  Steroid Receptor Coactivator-1 Coactivates Activating Protein-1-mediated Transactivations through Interaction with the c-Jun and c-Fos Subunits* , 1998, The Journal of Biological Chemistry.

[10]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[11]  I. Rusyn,et al.  WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. , 1998, Carcinogenesis.

[12]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[13]  P. Chambon,et al.  The Putative Cofactor TIF1α Is a Protein Kinase That Is Hyperphosphorylated upon Interaction with Liganded Nuclear Receptors* , 1998, The Journal of Biological Chemistry.

[14]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[15]  Y. Ouchi,et al.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. , 1998, Biochemical and biophysical research communications.

[16]  H. Erdjument-Bromage,et al.  A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. , 1998, Genes & development.

[17]  H. Gronemeyer,et al.  The nuclear receptor ligand-binding domain: structure and function. , 1998, Current opinion in cell biology.

[18]  J. Gustafsson,et al.  A regulatory role for RIP140 in nuclear receptor activation. , 1998, Molecular endocrinology.

[19]  D. Edwards,et al.  The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors* , 1998, The Journal of Biological Chemistry.

[20]  Andrew J. Bannister,et al.  The acetyltransferase activity of CBP stimulates transcription , 1998, The EMBO journal.

[21]  Hueng-Sik Choi,et al.  Steroid Receptor Coactivator-1 Interacts with the p50 Subunit and Coactivates Nuclear Factor κB-mediated Transactivations* , 1998, The Journal of Biological Chemistry.

[22]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[23]  B. Spiegelman.  PPARγ in Monocytes: Less Pain, Any Gain? , 1998, Cell.

[24]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[25]  S. Souza,et al.  BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. , 1998, Diabetes.

[26]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[27]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[29]  O. Jänne,et al.  CREB-binding protein in androgen receptor-mediated signaling. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[31]  J. T. Kadonaga,et al.  p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. , 1998, Genes & development.

[32]  M. Ito,et al.  Steroidogenic factor-1 contains a carboxy-terminal transcriptional activation domain that interacts with steroid receptor coactivator-1. , 1998, Molecular endocrinology.

[33]  C. Glass,et al.  Transcription factor-specific requirements for coactivators and their acetyltransferase functions. , 1998, Science.

[34]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[35]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[36]  M. Leid,et al.  p300 Functions as a Coactivator for the Peroxisome Proliferator-activated Receptor α* , 1997, The Journal of Biological Chemistry.

[37]  J. Lehmann,et al.  Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. , 1997, Chemistry & biology.

[38]  J. Mizukami,et al.  The Antidiabetic Agent Thiazolidinedione Stimulates the Interaction between PPARγ and CBP , 1997 .

[39]  J. Auwerx,et al.  Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.

[40]  M. Rao,et al.  Isolation and Characterization of PBP, a Protein That Interacts with Peroxisome Proliferator-activated Receptor* , 1997, The Journal of Biological Chemistry.

[41]  B. Spiegelman,et al.  Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.

[42]  Jeffrey D. Parvin,et al.  RNA Helicase A Mediates Association of CBP with RNA Polymerase II , 1997, Cell.

[43]  C. Allis,et al.  Steroid receptor coactivator-1 is a histone acetyltransferase , 1997, Nature.

[44]  G. Rodan,et al.  Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  A. Wolffe,et al.  Acetylation of general transcription factors by histone acetyltransferases , 1997, Current Biology.

[46]  M. Lazar,et al.  Peroxisome Proliferator Activated Receptor γ, CCAAT/ Enhancer-binding Protein α, and Cell Cycle Status Regulate the Commitment to Adipocyte Differentiation* , 1997, The Journal of Biological Chemistry.

[47]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[48]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[49]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  B. Spiegelman,et al.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. , 1997, Genes & development.

[51]  B. Spiegelman,et al.  Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. , 1997, Current opinion in lipidology.

[52]  J. Northrop,et al.  TNFα-Mediated Inhibition and Reversal of Adipocyte Differentiation Is Accompanied by Suppressed Expression of PPARγ without Effects on Pref-1 Expression. , 1997, Endocrinology.

[53]  J. Gimble,et al.  Decreased Expression of Murine PPARγ in Adipose Tissue during Endotoxemia. , 1997, Endocrinology.

[54]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[55]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[56]  M. Pazin,et al.  What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.

[57]  L. Leung,et al.  Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappaB activity. , 1997, Carcinogenesis.

[58]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[59]  M. Lazar,et al.  Stoichiometric and steric principles governing repression by nuclear hormone receptors. , 1997, Genes & development.

[60]  H. K. Bojes,et al.  Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. , 1997, Carcinogenesis.

[61]  C. Glass,et al.  Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors , 1997, Molecular and cellular biology.

[62]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[63]  P. Chambon,et al.  SUG1, a Putative Transcriptional Mediator and Subunit of the PA700 Proteasome Regulatory Complex, Is a DNA Helicase* , 1997, The Journal of Biological Chemistry.

[64]  B. Spiegelman,et al.  Functional Antagonism between CCAAT/Enhancer Binding Protein-α and Peroxisome Proliferator-activated Receptor-γ on the Leptin Promoter* , 1997, The Journal of Biological Chemistry.

[65]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[66]  B. Spiegelman,et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[68]  B. Cohen,et al.  Modulation of Insulin Activities by Leptin , 1996, Science.

[69]  B. Spiegelman,et al.  Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.

[70]  B. Spiegelman,et al.  Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.

[71]  L. Leung,et al.  Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kB activity , 1996 .

[72]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[73]  D. Livingston,et al.  The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[75]  M. D. Leibowitz,et al.  Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. , 1996, Endocrinology.

[76]  T. Hunter,et al.  A growing coactivator network , 1996, Nature.

[77]  B. O’Malley,et al.  CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Auwerx,et al.  Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. , 1996, The Journal of clinical investigation.

[79]  J. Haeggström,et al.  Lipid mediator networks in cell signaling: update and impact of cytokines 1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  Ralf Janknecht,et al.  Transcriptional control: Versatile molecular glue , 1996, Current Biology.

[81]  A. Takeshita,et al.  Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. , 1996, Endocrinology.

[82]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[83]  K. Umesono,et al.  SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[85]  M. Lazar,et al.  Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[87]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[88]  Margaret S. Wu,et al.  Down-regulation of the Expression of the Obese Gene by an Antidiabetic Thiazolidinedione in Zucker Diabetic Fatty Rats and db/db Mice (*) , 1996, The Journal of Biological Chemistry.

[89]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[90]  S. Detera-Wadleigh,et al.  Rat PPARδ Contains a CGG Triplet Repeat and Is Prominently Expressed in the Thalamic Nuclei , 1995 .

[91]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[92]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[93]  B. Spiegelman,et al.  Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J Auwerx,et al.  Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.

[95]  X. Chen,et al.  Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[96]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[97]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[98]  W. Wahli,et al.  Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more.... , 1995, Chemistry & biology.

[99]  B. Spiegelman,et al.  PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene , 1995, Molecular and cellular biology.

[100]  L. Rossetti,et al.  Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.

[101]  B. Spiegelman,et al.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[102]  J B Lawrence,et al.  Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. , 1994, Genes & development.

[103]  C. Dive,et al.  Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin , 1994, The Journal of cell biology.

[104]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[105]  J. Auwerx,et al.  Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. , 1993, European journal of biochemistry.

[106]  P. Yaciuk,et al.  p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. , 1993, Oncogene.

[107]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[108]  R. Heller,et al.  CCAAT/enhancer binding protein expression is rapidly extinguished in TA1 adipocyte cells treated with tumor necrosis factor. , 1992, Molecular endocrinology.

[109]  W. Lehmann,et al.  Peroxisomal degradation of leukotrienes by beta-oxidation from the omega-end. , 1991, The Journal of biological chemistry.

[110]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[111]  U. Smith,et al.  Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. , 1990, Metabolism: clinical and experimental.

[112]  J. Auwerx,et al.  Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus , 1988, Arteriosclerosis.

[113]  P. Drouin,et al.  Fenofibrate and human liver. Lack of proliferation of peroxisomes. , 1983, Archives of toxicology.

[114]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[115]  S. Misiti,et al.  Expression and hormonal regulation of coactivator and corepressor genes. , 1998, Endocrinology.

[116]  R. Evans,et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.

[117]  B. Spiegelman.  PPARgamma in monocytes: less pain, any gain? , 1998, Cell.

[118]  B. Seed,et al.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. , 1998, Nature.

[119]  N. Macdonald,et al.  Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). , 1998, Carcinogenesis.

[120]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. , 1998, Nature.

[121]  P. Libby,et al.  Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. , 1998, The American journal of pathology.

[122]  J. Auwerx,et al.  PPAR activators improve glucose homeostasis by changing fatty acid partitioning , 1998 .

[123]  L. Robertson,et al.  Activation of hepatic NF‐κB by the herbicide Dicamba (2‐methoxy‐3,6‐dichlorobenzoic acid) in female and male rats , 1998, Journal of biochemical and molecular toxicology.

[124]  J. Gimble,et al.  Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. , 1997, Endocrinology.

[125]  M. Lazar,et al.  Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. , 1997, The Journal of biological chemistry.

[126]  J. Mizukami,et al.  The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. , 1997, Biochemical and biophysical research communications.

[127]  M. Rao,et al.  Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. , 1996, Gene expression.

[128]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[129]  B. Blumberg,et al.  Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. , 1995, Gene expression.

[130]  D. Keppler,et al.  Peroxisomal leukotriene degradation: biochemical and clinical implications. , 1993, Advances in enzyme regulation.

[131]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[132]  D. Ron,et al.  Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). , 1992, The Journal of clinical investigation.